Dunnigan-type familial partial lipodystrophy associated with the heterozygous R482W mutation in LMNA gene — case study of three women from one family by Nabrdalik, Katarzyna et al.
306
Opis przypadku/Case repOrt
Endokrynologia Polska
DOI: 10.5603/EP.2013.0010
Tom/Volume 64; Numer/Number 4/2013
ISSN 0423–104X
Katarzyna Nabrdalik M.D., Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, 3 Maja St. 13–15, 41–800 
Zabrze, Poland, tel.: +48 32 370 44 15, e-mail: knabrdalik@yahoo.com
Dunnigan-type familial partial lipodystrophy associated 
with the heterozygous R482W mutation in LMNA gene — 
case study of three women from one family
Związek rodzinnej częściowej lipodystrofii typu Dunnigana z heterozygotyczną 
mutacją R482W w genie LMNA — opis przypadku trzech kobiet pochodzących 
z jednej rodziny
Katarzyna Nabrdalik1, Agnieszka Strózik1, Mariola Minkina-Pędras2, Przemysława Jarosz-Chobot2, 
Wojciech Młynarski3, Władysław Grzeszczak1, Janusz Gumprecht1
1Department of Internal Medicine, Diabetology and Nephrology, Medical University of Silesia, Zabrze, Poland 
2Department of Paediatrics, Endocrinology and Diabetes, Medical University of Silesia, Katowice, Poland 
3Department of Paediatrics, Oncology, Haematology and Diabetology, Medical University of Łódź, Poland
Abstract
Lipodystrophies are a heterogeneous group of diseases affecting adipose tissue distribution. Familial partial lipodystrophy of the Dun-
nigan type (FPLD) is a rare autosomal, dominant disorder caused by missense mutations in lamin A/C (LMNA) gene where selective 
loss of subcutaneous adipose tissue from the limbs and trunk, and accumulation of fat in the neck and face, is usually associated with 
a variety of metabolic disorders including insulin resistance, diabetes mellitus, dyslipidemia, hepatic steatosis and high blood pressure. 
In this report we present clinical and molecular features of three Polish women with FLPD phenotype coming from one family (a mother 
and her two daughters). FPLD was recognised under the circumstances of diabetes treatment, where sequencing of LMNA gene revealed 
heterozygous R482W mutation. In order to be able to recognise monogenic diabetes associated with lipodystrophy, it is important to be 
very precise in physical examination while diagnosing diabetes and to be aware of the necessity of performing genetic testing. Diabetes-
appropriate differential diagnosis is essential for the treatment strategy, anticipation of the disease progression, and determination of the 
prognosis. It is necessary for an individual mutation carrier to look carefully at the patient’s family. (Endokrynol Pol 2013; 64 (4): 306–310)
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Streszczenie
Lipodystrofie są heterogenną grupą chorób dotyczących rozmieszczenia tkanki tłuszczowej w organizmie. Rodzinna częściowa lipodystrofia 
typu Dunnigana (FPLD, familial partial lipodystrophy of the Dunnigan type) jest rzadkim autosomalnie dominującym schorzeniem, którego 
przyczyną jest mutacja braku sensu w genie laminy A/C (gen LMNA). W chorobie tej dochodzi do selektywnej utraty podskórnej tkanki 
tłuszczowej kończyn i tułowia oraz jej kumulacji w okolicy karku i twarzy, co zwykle jest związane z występowaniem różnych schorzeń 
metabolicznych, w tym insulinooporności, cukrzycy, dyslipidemii, stłuszczenia wątroby i nadciśnienia tętniczego. W przedstawionym 
raporcie opisujemy kliniczne i molekularne cechy trzech polskich kobiet pochodzących z jednej rodziny charakteryzujących się fenotypem 
FLPD (matka i jej dwie córki). Obecność FLPD rozpoznano w trakcie leczenia cukrzycy na podstawie sekwencjonowania genu LMNA 
i ujawnienia heterozygotycznej mutacji R482W. W celu rozpoznania cukrzycy monogenowej związanej z lipodystrofią ważne jest prze-
prowadzenie szczegółowego badania fizykalnego w toku diagnostyki cukrzycy oraz świadomość konieczności diagnostyki genetycznej 
wątpliwych przypadków. Prawidłowa diagnostyka różnicowa cukrzycy jest niezbędna w celu ustalenia strategii leczenia, przewidywania 
progresji choroby, określenia rokowania, a także jest potrzebna w celu wzmożenia czujności diagnostycznej w odniesieniu do rodziny 
osoby będącej nosicielem mutacji. (Endokrynol Pol 2013; 64 (4): 306–310)
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Introduction
Lipodystrophies are a rare, heterogeneous group of 
diseases affecting adipose tissue distribution that can be 
familial or acquired, generalised or partial. Affected pa-
tients are predisposed to metabolic complications such 
as insulin resistance, diabetes mellitus, hypertriglic-
erydaemia, hepatic steatosis, acanthosis nigricans and 
features characteristic for polycystic ovary syndrome 
namely hirsutism, oligomenorrhoea, and polycystic 
ovaries [1, 2]. Familial lipodystrophies can broadly be 
classified into two subtypes. These include autosomal 
recessive generalised lipodystrophy caused by muta-
tions of either seipin or AGPAT2 genes and autosomal 
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dominant partial lipodystrophy linked to mutation in 
the PPARG or LMNA genes [3–7]. LMNA is localised to 
chromosome 1q21 and encodes for the A-type lamins 
(lamin A and lamin C) arising by alternative splicing of 
the LMNA pre-mRNA that are expressed in most dif-
ferentiated somatic cells [8, 9]. Mutations in the LMNA 
gene cause a variety of monogenic, multisystem disor-
ders called laminopathies that comprise such diseases 
as skeletal and/or cardiac muscle dystrophies, axonal 
neuropathy, and premature ageing syndromes as well 
as familial partial lipodystrophy of Dunnigan type 
(FPLD; OMIM 151660) [10]. FPLD is one of the partial 
lipodystrophies, usually inherited, resulting from 
heterozygous missense mutations in the LMNA gene 
[11]. Approximately 90% of the FLPD-linked LMNA 
mutations generate aminoacid substitutions within an 
immunoglobulin-type domain of lamins A and C and 
it has been suggested that the immunoglobin-type fold 
in the tail of A-type lamins has a specific function in 
adipose tissue [12, 13]. The mutations affect the ability 
of A-type lamins to bind DNA which can potentially 
change adipocyte differentiation or survival [14]. The 
great majority of patients have heterozygous substitu-
tions within exon 8 at codon 482 which is suggested as 
a ‘hot spot’ for the disease [15]. Patients with FPLD are 
born with normal fat distribution and after puberty 
a regional loss of subcutaneous adipose tissue from ex-
tremities and trunk followed by progressive, excess fat 
accumulation on the face and neck, as well as the devel-
opment of metabolic complications, are observed. Due to 
accumulation of fat in the neck and upper trunk, FPLD 
can be misdiagnosed as Cushing’s syndrome [2, 16–18]. 
We present the case of a woman diagnosed with 
FPLD and her two daughters also affected by the 
disease.
Case presentation
Case No. 1
A 50 year-old woman with diabetes mellitus recognised at 
the age of 37 was admitted to the Department of Internal 
Medicine and Diabetology because of hyperglycaemia. 
On physical examination during admission she was 154 cm 
tall, weighed 54 kg and body mass index was 23 kg/m2. 
At the time of admission we noted fat accumulation 
around the face, neck and shoulders accompanied by 
thin limbs due to atrophy of subcutaneous adipose tissue, 
acanthosis nigricans in the cervical region and hirsutism. 
Laboratory tests revealed increased plasma blood glucose 
levels: fasting ones in the range of 122–130 mg/dL and 
prandial ones in the range of 164–223 mg/dL as well as 
HbA1c level of 6.6%. The blood cell count, liver func-
tion, creatinine level and uric acid levels were normal. 
Abnormalities in lipid parameters such as total choles-
terol — 6.93 mmol/L and triglycerides — 2.5 mmol/L 
were discovered, so lipid-lowering therapy (20 mg 
atorvastatin) was applied. Abdominal ultrasonography 
revealed slight hepatomegaly with features of hepatic 
steatosis. Hormonal tests (thyroid hormone and cortisol 
level) were normal. Blood pressure measurements were 
optimal and an had been treated with ACE-I and diuret-
ics. An ophthalmological examination revealed signs of 
hypertensive retinopathy. The insulin dose was escalated 
up to 56 units per day and metformin treatment was 
continued in order to obtain optimal blood glucose levels 
in a 24-hour profile.
She was diagnosed with gestational diabetes mel-
litus at the age of 36 and insulin therapy was initiated. 
After pregnancy blood glucose levels became normal, 
without the necessity for any treatment. Six months 
later fasting hyperglycaemia was noticed and she was 
initially treated with metformin and insulin. Her men-
arche was at the age of 11 years and she had irregular 
menstrual periods since adolescence. The woman has 
five children – three daughters and two sons and she 
has miscarried three other pregnancies. 
Due to typical phenotypic traits of lipodystrophy, 
accompanied by insulin resistance, acanthosis nigri-
cans, lipid abnormalities and a history of miscarriages, 
she was suspected of FPLD and genetic studies were 
performed. Her sons presented normal phenotype, but 
her two daughters aged 21 and 17 presented phenotype 
similar to the studied woman. All the children were 
considered to be healthy. The woman’s mother suffered 
from diabetes mellitus type 2 but her phenotype was 
not known. The woman did not know the medical his-
tory of her father. As soon as the outcome of the genetic 
study was obtained, we verified the misdiagnosed type 
2 diabetes mellitus and confirmed the FPLD2 as well 
as invited the woman’s five children to participate in the 
genetic examination. The woman’s sons, and her mother 
and father did not agree to participate in the study. 
The pedigree of the FPLD family with heterozygous 
R482W mutation in LMNA gene is presented at Figure 1.
Figure 1. Pedigree of FPLD family with heterozygous R482W 
mutation in LMNA gene 
Rycina 1. Rodowód rodziny z heterozygotyczną mutacją R482W 
w genie LMNA chorującej na FPLD
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Case No. 2
The 21 year-old daughter had a blood glucose level 
screening test performed, and because it displayed an 
abnormal outcome she was admitted to hospital. At the 
time of admission she was 164 cm tall, weighed 62 kg 
and body mass index was 23 kg/m2. She had moderate 
typical signs of diabetes mellitus such as polyuria and 
polydipsia. She presented typical phenotype character-
istic for lipodystrophy — fat accumulation around the 
face, neck, shoulders, upper back associated with lean 
muscular limbs and acanthosis nigricans in the cervical 
region, but unlike her mother she was free from signs of 
hirsutism. HbA1c level was 9.4%. Mean fasting plasma 
blood glucose level was in the range of 152–254 mg/dL 
and mean prandial plasma blood glucose level in the 
range of 157–344 mg/dL. Multiple injections of insulin 
therapy in conjunction with metformin were initiated. 
The blood cell count, creatinine level and uric acid level 
were normal but levels of liver enzymes (AST — 69 IU/L 
and ALT — 113 IU/L) and lipid parameters (triglycer-
ides — 2.14 mmol/L) were elevated. She was advised 
to implement a low fat diet and control the lipid profile 
after optimisation of blood glucose levels. Abdominal 
ultrasonography revealed slight hepatomegaly with 
features of hepatic steatosis as similarly observed in her 
mother. Hormonal tests (thyroid hormone and cortisol 
level) were normal. A performed electrocardiogram did 
not show any irregularities but her blood pressure was 
elevated up to 160/90 mm Hg. She required multidrug 
therapy in order to obtain good blood pressure control 
(calcium blocker, ACE-I, diuretic). On ophthalmologi-
cal examination, no signs of diabetic or hypertensive 
retinopathy were observed. The final insulin dose was 
escalated up to 90 units per day in order to obtain op-
timal blood glucose levels in a 24-hour profile. Her past 
medical history was insignificant. Her first menarche 
was at the age of 11 and she had regular menstruations. 
Genetic analysis was performed and FPLD recog-
nised and the young woman put under the care of 
a diabetologist. She has been successfully treated with 
functional intensive insulin therapy, diet and hyper-
tensive therapy. 
Case No. 3
The 17 year-old daughter had a blood glucose level 
screening test performed and, similarly to her sister, as 
it displayed an abnormal outcome she was admitted to 
hospital. She had had discrete symptoms of polydipsia 
and polyuria for a few days preceding admission. At 
the time of examination, she was 161 cm tall, weighed 
62 kg and body mass index was 23 kg/m2. She pre-
sented phenotype characteristic for lipodystrophy 
— fat accumulation around the face, neck, shoulders, 
upper back associated with lean muscular limbs, 
acromegaloid features including enlargement of jaw 
and moderate acanthosis nigricans on the neck. She, 
unlike her mother, was free from signs of hirsutism. 
Performed laboratory measurements revealed mean 
fasting plasma blood glucose level in the range of 
142–166 mg/dL, mean prandial plasma glucose level in 
the range of 160–180 mg/dL, HbA1c level of 7.4% and a 
fasting C-peptide level of 2.72 ng/mL (normal range: 
0.78–1.89). The girl was started on insulin therapy with 
the use of multiple injections. The blood cell count and 
creatinine level were within normal range. Liver pa-
rameters were elevated (AST — 87 IU/L and ALT — 129 
IU/L) but unlike her mother and sister, lipid profile was 
in the normal range and abdominal ultrasonography 
did not reveal any features of hepatomegaly or he-
patic steatosis. Polycystic ovaries were observed upon 
ultrasound examination and a diagnosis of polycystic 
ovary syndrome was established by the gynaecologist. 
Hormonal tests (thyroid hormone and cortisol level) 
were normal. Although there were no abnormalities 
in a performed electrocardiogram, echocardiography 
identified concentric left ventricular hypertrophy and 
24-h blood pressure monitoring revealed elevated 
above normal blood pressure values. Therefore anti-
hypertensive therapy with calcium blocker was initi-
ated and good blood pressure control was obtained. 
No signs of diabetic or hypertensive retinopathy were 
found on ophthalmological examination. The final in-
sulin dose was escalated up to 70 units per day in order 
to obtain optimal blood glucose levels in a 24-hour 
profile. Her past medical history was unremarkable. 
Pubertal development was normal with menarche 
at the age of 13 and she had irregular menstruations, 
similarly to her mother. 
Genetic analysis was performed and FPLD recog-
nised; the girl is under the care of a diabetologist and 
has been successfully treated with intensive insulin 
therapy, metformin and hypertensive therapy.
Genetic analysis
Genetic screening and analysis of the exon 8 in the 
LMNA gene were performed at the Childrens’ Hos-
pital and Centre for Medical Genetics and Molecular 
Medicine, Haukeland University Hospital in Bergen in 
Norway. Genomic DNA from each patient was isolated 
from peripheral blood lymphocytes using a commercial 
kit. All coding exons of LMNA with flanking intron 
sequences from the patients were amplified with PCR. 
DNA sequence information for the LMNA gene was ob-
tained from GenBank (accession no. NM_170708.3 and 
NM_170707.3 www.ncbi.nlm.nih.gov). For sequencing, 
all exons, exon–intron boundaries, and 900 bp from the 
5’ and 3’ untranslated region (UTR)/promoter region of 
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LMNA were amplified using PCR with sequence-specif-
ic primers and analysed by terminator cycle sequencing 
using Big Dye v3.0 chemistry on an ABI PRISM 310 
capillary DNA sequencer (Applied Biosystems, Foster 
City, CA, USA). All sequence data was compared to Ref-
Seq NM_006005 using Sequencher Software 4.7 (Gene 
Codes, Ann Arbor, MI, USA). Direct DNA sequencing 
revealed a heterozygous missense mutation at codon 
482 (c. 1444C > T; R482W) located in exon 8 of the LMNA 
gene in all three female patients’ blood samples. On 
the basis of revealed missense mutation W482R, the 
diagnosis of familial partial lipodystrophy of the Dun-
nigan type (FPLD) was established. Chromatograms 
from DNA sequencing of the affected female family 
members revealing the above mentioned mutation are 
presented in Figure 2. 
Discussion
We report a case of LMNA mutation R482W (c.1444C > 
T) in exon 8, in the heterozygous state, causing FPLD 
associated with a variety of metabolic complications. 
This mutation was identified among three women in 
one Polish family which has confirmed the diagnosis of 
FPLD suspected on the basis of phenotype typical for 
the disease [19]. Even though all three women carried 
the same mutation of LMNA gene and had diabetes 
mellitus, the type and severity of concomitant complica-
tions were differently pronounced. Insulin resistance 
was of various degrees, manifested by a large amount 
of insulin necessary to obtain good metabolic control 
of diabetes, the most highlighted in the 21 year-old 
daughter and the least in the mother. Two of the studied 
Figure 2. Chromatograms from DNA sequencing of affected female family members revealing heterozygous substitution c.1444C > 
T within exon 8 of LMNA gene. A. 50 year-old woman (mother). B. 21 year-old woman (daughter). C. 17 year-old girl (daughter)
Rycina 2. Chromatogramy sekwencjonowania DNA chorych członków rodziny ujawniające heterozygotyczną substytucję c.1444 C > 
T w obrębie exonu 8 genu LMNA. A. 50-letnia kobieta (matka). B. 21-letnia kobieta (córka). C. 17-letnia dziewczynka (córka)
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women had slight hepatomegaly with hepatic steatosis 
in ultrasonography examination, of which one was 
acompanied by elevated levels of liver enzymes and one 
woman had elevated liver enzymes with normal liver 
ultrasound examination. Apart from glucose and lipid 
abnormalities, we diagnosed hypertension in all the 
female patients and observed concentric hypertrophy 
of the left ventricle in one of them in performed echo-
cardiography. Unfortunately the other two described 
women had no echocardiography examination. All the 
women presented acanthosis nigricans but only the 
mother had hirsutism. Two of them presented men-
strual irregularities and one of them polycystic ovaries 
syndrome. Additionally, the mother had a history of 
multiple miscarriages. 
All the mentioned abnormalities are consistent 
with observations in FPLD patients in accordance with 
previous reports from literature [20, 21]. On the other 
hand, none of the patients was overweight, while most 
of the patients carrying the W482R mutation described 
to date have had BMI above the normal range [22, 23]. 
Although the molecular basis and precise pathophysiol-
ogy of FPLD is still not fully known, early diagnosis of 
Dunnigan-type familial partial lipodystrophy caused 
by mutation in LMNA gene should be performed when 
characteristic FPLD phenotype with concomitant one 
or more metabolic abnormalities are observed. This 
implies that all family members of the studied women 
should be carefully diagnosed to allow appropri-
ate medical care and clinical treatment if necessary. 
Unfortunately, in the case of the presented patients, 
other members of the family, namely two sons and the 
mother’s parents, could not be examined. 
All three women visit our Outpatient Clinic regu-
larly, so it will be interesting to observe whether there 
will be any problems with conception and miscarriages 
among the two daughters in the future, a problem 
observed in the past medical history of the mother. It 
ought to be mentioned that monogenic forms of diabe-
tes account only for a few percent of the disease cases 
and are not easy to recognise [24]. Diabetes associated 
with FLPD may be misdiagnosed with type 2 diabetes, 
but proper diagnosis influences future treatment deci-
sions and prognosis, and may help early recognition of 
affected members of the patient’s family.
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